Cutera (CUTR) Stock Price, News & Analysis

Company Overview

Cutera, Inc. provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform. It also offers truSculpt, a high-powered radio frequency system designed for circumferential reduction, lipolysis, and deep tissue heating and treat all skin types; Secret RF, a fractional RF microneedling device that delivers heat into the deeper layers of the skin using controlled RF energy; and Enlighten SR/III, a laser platform with a dual wavelength for multi-colored tattoo removal, and the treatment of benign pigmented lesions and acne scars. In addition, the company provides Excel HR, a hair removal solution for all skin types; xeo, a multi-application platform for the removal of unwanted hair, treatment of vascular lesions, and skin revitalization by treating discoloration, fine lines, and laxity; and Secret DUO, two dual non-ablative fractional technologies that can be used individually or in combination to target a variety of aesthetic concerns and skin conditions on all skin types with little to no downtime. Further, it offers its products through direct sales and services, and network of distributors and direct international sales. Cutera, Inc. was incorporated in 1998 and is headquartered in Brisbane, California.

Key Stats

• Today's Range: $0.09 to $0.11
• 50-Day Range: $0.04 to $0.13
• 52-Week Range: $0.09 to $2.88
• Volume: 27.70 million shs
• Average Volume: 2.41 million shs
• Market Capitalization: $787,254.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Moderate Buy

CUTR Stock Analysis - Frequently Asked Questions

How have CUTR shares performed this year?

Cutera's stock was trading at $0.3529 at the start of the year. Since then, CUTR stock has decreased by 88.9% and is now trading at $0.0390.
View the best growth stocks for 2025 here.

How were Cutera's earnings last quarter?

Cutera, Inc. (NASDAQ:CUTR) posted its quarterly earnings data on Thursday, November, 7th. The medical device company reported ($1.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by $0.98. The medical device company had revenue of $32.50 million for the quarter, compared to analyst estimates of $32.57 million.
Read the conference call transcript.

How do I buy shares of Cutera?

Shares of CUTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cutera own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cutera investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Visa (V) and Netflix (NFLX).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Computer and Technology
• Industry: Electromedical equipment
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:CUTR
• CIK: 1162461
• Web: www.cutera.com
• Phone: (415) 657-5500
• Fax: 415-330-2444
• Employees: 460
• Year Founded: 1998

Price Target and Rating

• Average Stock Price Target: $3.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +7,592.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($6.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-162,830,000.00
• Net Margins: -84.86%
• Pretax Margin: -91.81%
• Return on Equity: N/A
• Return on Assets: -45.07%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.88
• Quick Ratio: 1.86

Sales & Book Value

• Annual Sales: $155.21 million
• Price / Sales: 0.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($8.62) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 20,186,000
• Free Float: 20,101,000
• Market Cap: $787,254.00
• Optionable: Optionable
• Beta: 1.36